Design and synthesis of 4-phenyl piperidine compounds targeting the mu receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 21, 2004, Pages 5275-5279

  Chen, Zhengming ^a   Davies, Ellen ^a   Miller, Wendy S ^a   Shan, Shen ^a   Valenzano, Kenneth J ^a   Kyle, Donald J ^a  

^a PURDUE PHARMA L P   (United States)

Author keywords

Agonist; Chemistry; Design; Mu agonist; Mu receptor; ORL 1 receptor; SAR; Structure activity

Indexed keywords

LOPERAMIDE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; PIPERIDINE DERIVATIVE;

ARTICLE; DRUG DESIGN; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION;

CELL LINE; HUMANS; PIPERIDINES; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 5344260443     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.08.032     Document Type: Article

References (25)

1. A. Kaczor, and D. Matosiuk Curr. Med. Chem. 9 2002 1567 1589
2. A. Kaczor, and D. Matosiuk Curr. Med. Chem. 9 2002 1591 1603
3. T. Komoto, T. Okada, S. Sato, Y. Niino, T. Oka, and T. Sakamoto Chem. Pharm. Bull. 49 2001 1314 1320
4. S. Sato, T. Komoto, Y. Kanamaru, N. Kawamoto, T. Okada, T. Kaiho, K. Mogi, S. Morimoto, N. Umehara, T. Koda, A. Miyashita, T. Sakamoto, Y. Niino, and T. Oka Chem. Pharm. Bull. 50 2002 292 297
5. C. Mollereau, M. Parmentier, P. Mailleux, J.-L. Butour, C. Moisand, P. Chalon, D. Caput, G. Vassart, and J.-C. Meunier FEBS Lett. 341 1994 33 38
6. K. Fukuda, S. Kato, K. Mori, M. Nishi, H. Takeshima, N. Iwabe, T. Miyata, T. Houtani, and T. Sugimoto FEBS Lett. 343 1994 42 46
7. Y. Chen, Y. Fan, J. Liu, A. Mestek, M. Tian, C.A. Kozak, and L. Yu FEBS Lett. 347 1994 279 283
8. J.-C. Meunier, C. Mollereau, L. Toll, C. Suaudeau, C. Moisand, P. Alvinerie, J.-L. Butour, J.-C. Guillemot, P. Ferrara, B. Monsarrat, H. Mazargil, G. Vassart, M. Parmentier, and J. Costentin Nature (London) 377 1995 532 535
9. R.K. Reinscheid, H.-P. Nothacher, A. Bourson, A. Ardati, R.A. Henningsen, J.R. Bunzow, D.K. Grady, H. Langen, F.J. Monsma Jr., and O. Civelli Science (Washington, DC) 270 1995 792 794
10. Z. Chen, W. Miller, S. Shan, and K. Valenzano Bioorg. Med. Chem. Lett. 13 2003 3247
11. Drug Discovery Today 8 24 2003 1140 1141
12. Z. Chen, R.R. Goehring, K. Valenzano, and D.J. Kyle Bioorg. Med. Chem. Lett. 14 2004 1347
13. D.L. DeHaven-Hudkins, L.C. Burgos, J.A. Cassel, J.D. Daubert, R.N. DeHaven, E. Mansson, H. Nagasaka, G. Yu, and T. Yaksh J. Pharmacol. Exp. Ther. 289 1999 494 502
14. H.E. Shannon, and E.A. Lutz Neuropharmacology 42 2002 253 261
15. J.A. Reichert, R.S. Daughters, R. Rivard, and D.A. Simone Pain 89 2001 221 227
16. D.L. DeHaven-Hudkins, A. Cowan, B.L. Cortes, J.D. Daubert, J.A. Cassel, R.N. DeHaven, G.B. Kehner, and V. Kumar Life Sci. 71 2002 2787 2796
17. R.A. Stokbroekx, J. Vandenberk, A.H. Van Heertum, G.M. Van Laar, M.J. Van der Aa, W.F. Van Bever, and P.A. Janssen J. Med. Chem. 16 1973 782 786
18. G.W. Adelstein, C.H. Yen, E.Z. Dajani, and R.G. Bianchi J. Med. Chem. 19 1976 1221 1225
19. 3): δ ppm 1.7 (d, 2H), 2.7-2.8 (m, 4H), 3.2-3.3 (m, 2H), 3.3-3.4 (m, 2H), 3.6-3.7 (m, 2H), 4.1 (t, 1H), 7.2-7.25 (m, 2H), 7.3-7.4 (m, 8H), 7.6 (m, 2H), 7.8 (m, 1H), 7.9 (s, 1H). LC/MS: 456.0 (M+1). >97% pure in LC
20. C. Zhang, W. Miller, K. Valenzano, and D.J. Kyle J. Med. Chem. 45 2002 5280 5286
21. C. Cometta-Morini, P.A. Maguire, and G.H. Loew Mol. Pharmacol. 41 1992 185 196
22. C.J.E. Niemegeers, F. Awouters, and F.M. Lenaerts Drug Develop. Res. 8 1986 279 286
23. K.J. Valenzano, W. Miller, Z. Chen, S. Shan, G. Crumley, S.F. Victory, E. Davies, J.C. Huang, N. Allie, S.J. Nolan, Y. Rotshteyn, D.J. Kyle, and K. Brogle J. Pharmacol. Exp. Ther. 310 2004 783 792
24. G.T. Whiteside, J.E. Harrison, M.S. Pearson, Z. Chen, Y. Rotstheyn, P.I. Turchin, J.D. Pomonis, L. Mark, K. Walker, and K.C. Brogle J. Pharmacol. Exp. Ther. 310 2004 793 799
25. Chen, Z.; Davies, E.; Victory, S.; Huang, J.; Valenzano, K.; Miller, W.; Shan, S.; Rotstheyn, Y.; Whiteside, G.; Brogle, K.; Kyle, D. 227th ACS National Meeting, Anaheim, CA, United States, March 28-April 1, 2004, MEDI-186